India, Oct. 27 -- Swiss drug major Novartis AG (NVS,NOVN.SW) reported Tuesday sharply lower profit in its third quarter, mainly hurt by an impairment charge and higher expenses, despite growth in net sales.
Further, the firm raised fiscal 2026 outlook for core operating income and confirmed sales growth view.
Vas Narasimhan, CEO of Novartis, said, "Novartis delivered solid sales growth in Q3, as priority brands and launches more than offset generic erosion, demonstrating the replacement power of the business. Combined with productivity efforts, this drove strong bottom line performance and allowed us to upgrade our full-year guidance.... With continued momentum across the business and pipeline, we remain well on track to deliver our mid- ...